Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Korean Air anticipates uncertainties in the business environment this year due to shifts in the global political landscape, ...

Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...

Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine ...

TOKYO -- Japan's Mitsubishi Chemical Group announced on Friday the agreed sale of its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to U.S. investment fund Bain Capital for approximately 510 ...